Recent studies have demonstrated a considerable prevalence of hypogonadism in diabetic men when compared to non-diabetics, reporting an association between testosterone deficiency and visceral obesity, insulin resistance and erectile dysfunction. Hypogonadism is commonly associated with Type 2 DIABETES MELLITUS, being defined as the presence of suggestive symptoms of hypogonadism associated with an evaluation of testosterone serum levels. The objectives of this research was to evaluate the prevalence of male hypogonadism among patients diagnosed with Type 2 DIABETES MELLITUS at the Endocrinology Outpatient Clinic of the Hospital de Jean from Belém - Pará, Brazil, and to evaluate the relationship between testosterone levels, body mass index, the duration of the illness, glycemic control and erectile dysfunction. It is a descriptive, individual, observational, analytical and cross-sectional study of a group of 46 male patients with type 2 DIABETES MELLITUS and a control group composed of 46 male patients, all of them admitted at the Endocrinology Service and Metabolism of Clinic of the Hospital de Jean. Serum dosage values are shown on average numbers and for statistical analysis the GraphPad Prisma 5.0 and BioEstat 5.0 programs were used. Differences between these groups were analyzed using the Kruskal-Wallis tests, Mann-Whitney U-test, and Student's T-Test, as appropriate. The correlations between two variables were determined by Spearman's correlation analysis. The significance level was set at 5% (p value <0.05). The average age of diabetic patients was 55 ± 7 years-old; weight 80.4 ± 18.4 kg; BMI 29.6 ± 5.9 and glycated hemoglobin 8.24 ± 1.9 percent. The prevalence of hypogonadism was 23.9% (n = 9). The testosterone levels found were inversely correlated with glycated hemoglobin showing statistical significance (r = -0.432, p <0.01). The influence of glycemic control on plasma testosterone levels (p <0.05) was also observed. The erectile dysfunction was correlated with both testosterone levels (p <0.05) and HbA1c (p <0.05). The prevalence of low testosterone levels in type 2 diabetic men ratifies the benefit perspective of the male hypogonadism screening in the population represented by this research.
|
